載入...
Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia
BACKGROUND: Preclinical and clinical studies suggest amantadine immediate-release (IR) may reduce dyskinesia in Parkinson’s disease (PD), although higher doses are associated with increased CNS adverse events (AEs). ADS-5102 is an extended release amantadine capsule formulation, designed for once-da...
Na minha lista:
| 發表在: | Clin Pharmacokinet |
|---|---|
| Main Authors: | , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Springer International Publishing
2018
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6325984/ https://ncbi.nlm.nih.gov/pubmed/29777529 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40262-018-0663-4 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|